{"id":4315,"date":"2026-04-13T10:00:28","date_gmt":"2026-04-13T08:00:28","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=4315"},"modified":"2026-03-25T16:17:40","modified_gmt":"2026-03-25T15:17:40","slug":"a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/","title":{"rendered":"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Data from the CASSANDRA trial, <a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(25)01685-X\/abstract\" target=\"_blank\" rel=\"noopener\">recently published on The Lancet<\/a>, show a significant improvement in event-free survival for preoperative PAXG compared with mFOLFRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.<\/p>\n<p>CASSANDRA trial is a randomized open-label Italian study that involved 132 adult patients with stage I-III resectable or borderline resectable pancreatic ductal adenocarcinoma. Participants were first randomly assigned PAXG (capecitabine, cisplatin, nab-paclitaxel and gemcitabine) or mFOLFIRINOX (fluorouracil, leucovorin, irinotecan and oxaliplatin) for 4 months, followed by a second randomization to 2 months of additional chemotherapy either before or after surgery.\u00a0Event-free survival was 16 months with PAXG versus 10.2 months with mFOLFRINOX; moreover, PAXG not only prolongs event-free survival, but also increases the rate of disease control, pathological complete response and node- negative resections, and reduces the incidence of intra or early postoperative metastases. As authors point out, \u00abAccording to subgroup analysis, the treatment effect consistently favoured PAXG across all the subpopulations. Furthermore, the PAXG regimen did not increase treatment-related toxicity and caused a clinically meaningful deterioration of quality of life in a smaller number of domains compared with mFOLFIRINOX. Neoadjuvant therapy should be indicated as standard-of-care for patients with non-metastatic pancreatic ductal adenocarcinoma before surgery. CASSANDRA sets PAXG as a new standard regimen for preoperative treatment of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. Exploring the underlying biological mechanisms that guide the identification of the patients\u2019 subgroups benefiting or not from preoperative therapy is a paramount important challenge\u00bb, they conclude.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;4325&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]Data from the CASSANDRA trial, recently published<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":4325,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-4315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-13T08:00:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/04\/Image_Lancet_13Apr26-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1587\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma\",\"datePublished\":\"2026-04-13T08:00:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/\"},\"wordCount\":317,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Image_Lancet_13Apr26-scaled.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/\",\"name\":\"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Image_Lancet_13Apr26-scaled.jpg\",\"datePublished\":\"2026-04-13T08:00:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Image_Lancet_13Apr26-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/Image_Lancet_13Apr26-scaled.jpg\",\"width\":2560,\"height\":1587},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma - Fondazione Gianni Bonadonna","description":"Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/","og_locale":"en_US","og_type":"article","og_title":"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma - Fondazione Gianni Bonadonna","og_description":"Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2026-04-13T08:00:28+00:00","og_image":[{"width":2560,"height":1587,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/04\/Image_Lancet_13Apr26-scaled.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma","datePublished":"2026-04-13T08:00:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/"},"wordCount":317,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/04\/Image_Lancet_13Apr26-scaled.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/","name":"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/04\/Image_Lancet_13Apr26-scaled.jpg","datePublished":"2026-04-13T08:00:28+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/04\/Image_Lancet_13Apr26-scaled.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/04\/Image_Lancet_13Apr26-scaled.jpg","width":2560,"height":1587},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/a-comparison-of-mfolfrinox-versus-paxg-in-pancreatic-ductal-adenocarcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"A comparison of mFOLFRINOX versus PAXG in pancreatic ductal adenocarcinoma"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=4315"}],"version-history":[{"count":3,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4315\/revisions"}],"predecessor-version":[{"id":4330,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4315\/revisions\/4330"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/4325"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=4315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=4315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=4315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}